PMID- 25788221
OWN - NLM
STAT- MEDLINE
DCOM- 20160316
LR  - 20220310
IS  - 1952-4013 (Electronic)
IS  - 1167-1122 (Linking)
VI  - 25
IP  - 2
DP  - 2015 Apr
TI  - Clinical observation of panniculitis in two patients with BRAF-mutated metastatic 
      melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor.
PG  - 177-80
LID - 10.1684/ejd.2014.2512 [doi]
AB  - BACKGROUND: Treatment with selective BRAF or MEK inhibitors is frequently 
      associated with cutaneous toxicities, including squamous cell carcinoma (SCC), 
      papillomas and rash. These cutaneous adverse effects are typically observed at a 
      lower incidence during combined BRAF and MEK inhibitor therapy. PATIENTS AND 
      METHODS: Two male patients with stage IV metastatic BRAF-mutated melanoma were 
      treated with a combination of a selective BRAF inhibitor and a selective MEK 
      inhibitor (dabrafenib and trametinib, or encorafenib (LGX818) and binimetinib 
      (MEK162)) within two different clinical trials. Ten and 150 days after treatment 
      start respectively, the patients developed painful nodules on the legs. In 
      addition, one patient developed symmetrical articulation pain and intermittent 
      fever episodes. RESULTS: Based on the clinical and histological presentation, 
      erythema nodosum-like panniculitis was diagnosed in both cases. No other 
      aetiology could be found. After receiving topical or oral steroid treatment and 
      anti-inflammatory analgesics, the painful nodular lesions disappeared several 
      weeks later. In one case, a rebound of the painful nodules was observed when the 
      combination treatment (dabrafenib and trametinib) was resumed after a 1-week 
      unscheduled treatment interruption. CONCLUSIONS: Panniculitis has previously been 
      described in association with BRAF inhibitor treatment, but not MEK inhibitor 
      treatment. Combination treatment is usually associated with a lower incidence of 
      cutaneous adverse events (AEs), as compared to monotherapy. Panniculitis was 
      observed in two patients during combined BRAF and MEK inhibitor treatment. These 
      cases illustrate the need for further research in a larger patient population to 
      identify a possible link between combined BRAF and MEK inhibitor treatment and 
      the incidence of panniculitis.
FAU - Galliker, Nadja A
AU  - Galliker NA
AD  - University Hospital of Zurich Department of Dermatology Gloriastrasse 31 CH-8091 
      Zurich Switzerland.
FAU - Murer, Carla
AU  - Murer C
AD  - University Hospital of Zurich Department of Dermatology Gloriastrasse 31 CH-8091 
      Zurich Switzerland.
FAU - Kamarashev, Jivko
AU  - Kamarashev J
AD  - University Hospital of Zurich Department of Dermatology Gloriastrasse 31 CH-8091 
      Zurich Switzerland.
FAU - Dummer, Reinhard
AU  - Dummer R
AD  - University Hospital of Zurich Department of Dermatology Gloriastrasse 31 CH-8091 
      Zurich Switzerland.
FAU - Goldinger, Simone M
AU  - Goldinger SM
AD  - University Hospital of Zurich Department of Dermatology Gloriastrasse 31 CH-8091 
      Zurich Switzerland.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - France
TA  - Eur J Dermatol
JT  - European journal of dermatology : EJD
JID - 9206420
RN  - 0 (Benzimidazoles)
RN  - 0 (Carbamates)
RN  - 0 (Imidazoles)
RN  - 0 (Oximes)
RN  - 0 (Pyridones)
RN  - 0 (Pyrimidinones)
RN  - 0 (Sulfonamides)
RN  - 181R97MR71 (binimetinib)
RN  - 33E86K87QN (trametinib)
RN  - 8L7891MRB6 (encorafenib)
RN  - EC 2.7.11.1 (BRAF protein, human)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinases)
RN  - QGP4HA4G1B (dabrafenib)
SB  - IM
MH  - Adult
MH  - Antineoplastic Combined Chemotherapy Protocols/*adverse effects
MH  - Benzimidazoles/administration & dosage
MH  - Carbamates/administration & dosage
MH  - Humans
MH  - Imidazoles/administration & dosage
MH  - Male
MH  - Melanoma/*drug therapy/genetics/secondary
MH  - Mitogen-Activated Protein Kinases/antagonists & inhibitors
MH  - Oximes/administration & dosage
MH  - Panniculitis/*chemically induced
MH  - Proto-Oncogene Proteins B-raf/antagonists & inhibitors/*genetics
MH  - Pyridones/administration & dosage
MH  - Pyrimidinones/administration & dosage
MH  - Skin Neoplasms/*drug therapy/genetics/pathology
MH  - Sulfonamides/administration & dosage
OTO - NOTNLM
OT  - BRAF inhibition
OT  - MEK inhibition
OT  - adverse event
OT  - melanoma
OT  - panniculitis
OT  - targeted therapy
EDAT- 2015/03/20 06:00
MHDA- 2016/03/17 06:00
CRDT- 2015/03/20 06:00
PHST- 2015/03/20 06:00 [entrez]
PHST- 2015/03/20 06:00 [pubmed]
PHST- 2016/03/17 06:00 [medline]
AID - ejd.2014.2512 [pii]
AID - 10.1684/ejd.2014.2512 [doi]
PST - ppublish
SO  - Eur J Dermatol. 2015 Apr;25(2):177-80. doi: 10.1684/ejd.2014.2512.